Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy

BACKGROUND: Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer whose incidence is growing parallel to the lengthening of the average lifespan. Cemiplimab, an antiPD-1 monoclonal antibody, is the first approved immunotherapy for patients with locally advanced CSCC (laCSCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Strippoli, Sabino, Fanizzi, Annarita, Quaresmini, Davide, Nardone, Annalisa, Armenio, Andrea, Figliuolo, Francesco, Filotico, Raffaele, Fucci, Livia, Mele, Fabio, Traversa, Michele, De Luca, Federica, Montagna, Elisabetta Sara, Ruggieri, Eustachio, Ferraiuolo, Simona, Macina, Francesco, Tommasi, Stefania, Sciacovelli, Angela Monica, De Risi, Ivana, Albano, Anna, Massafra, Raffaella, Guida, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606572/
https://www.ncbi.nlm.nih.gov/pubmed/34820323
http://dx.doi.org/10.3389/fonc.2021.686308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606572/
https://www.ncbi.nlm.nih.gov/pubmed/34820323
http://dx.doi.org/10.3389/fonc.2021.686308

Ejemplares similares